- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Christine Simmon Discusses the Purple Book, Patents, and Biosimilars
Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Christine Simmon, JD, is the senior vice president of policy & strategic alliances of the Association for Accessible Medicines (AAM) and the executive director of AAM’s Biosimilars Council.
Transcript:
Tell us about the Purple Book and what it will mean for biosimilar makers and patent thickets.
The Purple Book is an FDA version of the current Orange Book. And so what it does is it provides sort of a cheat sheet for biosimilar and other people interested in biosimilar manufacturing and uptake to see what the reference product biologics are and whether or not there are biosimilars currently approved for those products and sort of what we can expect. It's a helpful tool that the FDA has recently made more helpful by rendering it searchable electronically. So, that's a positive development. I think that the Purple Book still suffers from not having mandatory listings of all the patents related to the biologic reference product. That is something that the agency, the FDA, cannot impose by itself, and so legislation would be required for that. And fortunately, there is legislation introduced by Senator Susan Collins [R-ME] to require that the Purple Book include all the patents for a biologic reference product. That would go a long way for biosimilar manufacturers looking to get into those products.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
